Flash | US Biotechnology and Pharmaceuticals Novartis 2Q26 EPS call readthrough: Growth drivers deliver as pivotal catalysts move closer CITI'S TAKE Novartis (covered by Graham Parry) reported 2Q26 revenue of $14.4B (+$464M vs. BBG cons) and adjusted EPS of $2.40/sh (+$0.24/sh), returning to sales growth (+3% y/y) as worldwide growth drivers offset Entresto ($1.1B; -$111M; -50% y/y) biosimilar erosion. Kisqali ($1.7B; +$13M; +43% y/y), Kesimpta ($1.4B; +$122M; +43% y/y), Scemblix ($562M; +$103M; +89% y/y), ...